5 edition of Anticancer Drug Resistance found in the catalog.
December 31, 1994
Written in English
|Contributions||Lori J. Goldstein (Editor), Robert F. Ozols (Editor)|
|The Physical Object|
|Number of Pages||304|
Chemistry and Pharmacology of Anticancer Drugs is a comprehensive survey of all families of anticancer agents currently in use or in advanced stages of clinical trials, including biologicals. The book is unique in providing molecular structures for all anticancer drugs, discussing them in terms of history, chemistry, mechanism of action. CiteScore: ℹ CiteScore: CiteScore measures the average citations received per document published in this title. CiteScore values are based on citation counts in a given year (e.g. ) to documents published in three previous calendar years (e.g. – 14), divided by the number of documents in these three previous years (e.g. – 14).
This book presents a thorough and authoritative overview of the multifaceted field of antibiotic science – offering guidance to translate research into tools for prevention, diagnosis, and treatment of infectious diseases. Provides readers with knowledge about the broad field of drug resistance. The microenvironment and drug resistance / Patrice J. Morin Glutathione and glutathione S-transferase in drug resistance / Victoria J. Findlay, Danyelle M. Townsend and Kenneth D. Tew Metallothioneins in drug resistance / Faiyaz Notta and D. James Koropatnick
Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment Tatsuya Usui, 1 Masashi Sakurai, 2 Shuhei Enjoji, 3 Hideyoshi Kawasaki, 3 Koji Umata, 3 Takashi Ohama, 3 Nobuyuki Fujiwara, 3 Ryotaro Yabe, 3 Shunya Tsuji, 3 Hideyuki Yamawaki, 4 Shoichi Hazama, 5, 6 Hiroko Cited by: ISBN: OCLC Number: Description: xiii, pages: illustrations ; 25 cm. Contents: 1. Genetics of drug resistance / June L. Biedler and Barbara A. Spengler P-glycoprotein homologues / Ellen Buschman, Pierre Lepage and Philippe Gros Role of protein kinase C in multidrug resistance / Catherine A. O'Brian, Nancy E. Ward, Karen R. Gravitt and Dominic Fan.
variant readings of the Qurān̓
The influence of the Enlightenment on the French Revolution
From airship to spaceship
Catechism of the history of the United States
Seminar on Manufacturing simulating the future
The theory and practice of real estate finance
Cooperation and helping behaviour
relation of gender and cultural individualism or collectivism to moral development
Neo Rauch: on the occasion of the ceremony and Exhibition for the Second Edition of The Vincent Van Gogh Bi-Annual Award for Contemporary Art in Europe.
Political parties in the new Europe
world of Ottoman art
When all else fails
Anticancer Drug Resistance (Cancer Treatment and Research) Softcover reprint of the original 1st ed. EditionCited by: In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic : Hardcover.
Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with overcancer-related deaths per year.
Clearly, the. Over the last 50 years, drug development and clinical trials have resulted in successful complete Anticancer Drug Resistance book in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with overcancer-related deaths per year.
Clearly, the Price: $ Anticancer Drug Resistance. Cancer Treatment and Research (Book 73) Share your thoughts Complete your review. Tell readers what you thought by rating and reviewing this book. Rate it Brand: Springer US. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance.
It is clear that drug resistance is complex, and many mechanisms exist by which cancer. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e.
g., adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance.
Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death.
A detailed description of the pharmacology, mechanisms of action, toxicity, resistance mechanisms, and clinical usefulness of each class of drugs is given. The authors emphasize concepts involved in determining the mechanism of action and development of resistance, the determinants of drug responsiveness to chemotherapeutic agents, and a rationale for their clinical use in various types of 2/5(1).
Cancer drug resistance is a complex phenomenon that is influenced by drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, EMT, inherent cell heterogeneity, epigenetic effects, or any combination of these by: Therefore, Pharmacology of Anti-Cancer Drugs will also have a particular interest in the following issues: The synergy between chemotherapy and other anticancer modalities, including radio- immuno- and gene therapy; the use of nanoscale particles or targeting moieties to improve drug bioavailability; and the identification of biomarkers derived from proteomics, and genomics or imaging technologies to predict response or resistance to drug treatment.
Cancer cells have the capacity to develop multidrug resistance (MDR), a key determinant of chemoresistance. A large fraction of cancer cells can be initially eradicated by anticancer regimens; however, a subset of malignant cells may escape the cytotoxic drug effects, due to the acquisition of de novo mutations and genetic alterations (acquired resistance) or due to pre-existing mechanisms of Cited by: 4.
Sample Online Issue of ANTICANCER RESEARCH. September, issue. OPEN ACCESS BACK FILES. All content of ANTICANCER RESEARCH published between vol. 24, - vol. 35, is online available free to all. Access Anticancer Research at your Mobile Device.
Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin.
Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also Cited by: Colorectal cancer (CRC) is one of the most aggressive cancers worldwide.
Several anticancer agents are available to treat CRC, but eventually cancer relapse occurs. One major cause of chemotherapy failure is the emergence of drug-resistant tumor cells, suspected to Cited by: Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development.
This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition Cited by: In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug.
Anticancer Drug Resistance by Lori J. Goldstein,available at Book Depository with free delivery worldwide. Explains the biological basis of cancer treatment and the role of chemists in improving anticancer drugs* Provides the historical background and serves as a comprehensive and practical guide on cancer research and anticancer drug development* Includes coverage of different approaches to treating cancer, drug resistance, and a chapter on cancer.
Drug resistance in cancer is a well-known phenomenon that results when cancer becomes tolerant to pharmaceutical treatment. Resistance to anticancer drugs arises from a wide variety of factors, such as genetic mutations and/or epigenetic changes, conserved but upregulated drug efflux, and various other cellular and molecular mechanisms.
Cisplatin resistance occurs when cancer cells develop an enhanced ability to reverse such damage by removing the cisplatin from DNA and repairing any damage done. The cisplatin-resistant cells upregulate expression of the excision repair cross-complementing (ERCC1) gene and protein.However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied.
The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to. Chapter Drugs That Modulate Resistance to Antitumor Agents. 1. ATP-Binding Cassette Efflux Pumps in Anticancer Drug Resistance. General features of ABC efflux pumps.
P-glycoprotein. 2. Glutathione and Glutathione-S-Transferase in Anticancer Drug Resistance. Inhibitors of glutathione biosynthesis.
Inhibitors of Book Edition: 1.